Harnessing CRISPR interference to re-sensitize laboratory strains and clinical isolates to last resort antibiotics

Abstract excerpt

The global race against antimicrobial resistance requires novel antimicrobials that are not only effective in killing specific bacteria, but also minimize the emergence of new resistances. Recently, CRISPR/Cas-based antimicrobials were proposed to address killing specificity with encouraging results. However, the emergence of target sequence mutations triggered by Cas-cleavage was identified as an escape strategy,...

Topics

Open a Topic to create a Post that cites this publication.

• Anti-Bacterial Agents
• Anti-Infective Agents
• CRISPR and Genetic Engineering
• CRISPR-Cas Systems
• Drug Resistance, Bacterial
• Escherichia coli
• Microbial Sensitivity Tests
• Mutation

Identifiers and source

Literature Corpus work

e158a4d2-6d0c-5a39-95e7-3a5b5cedf3bb

DOI

10.1101/2024.07.30.604783